Immucell Corp
Animal health biologics company developing, manufacturing and commercializing products that improve the health and productivity of neonatal dairy and beef calves, including the First Defense product line
Bought 170.0K
Granted 18.8K · Bought 128.9K
Granted 87.5K · Bought 53.5K
Granted 60.5K · Bought 26.5K · Sold 10.0K
Bought 88.8K
Bought 30.0K
Sold 15.0K
Bought 14.0K
Granted 15.0K · Bought 13.4K
Granted 7.5K
Granted 2.0K · Bought 5.2K
Granted 4.3K · Bought 2.0K
Granted 3.5K
Bought 1.0K
Bought 1.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Pessin Norman HSee Explanation of Responses · 1 transaction | — | 650.0Kas of Jul 2017 | — | 170.0K | — |
| Rothschild Jonathan EDirector · 218 transactions | — | 514.0Kas of Jun 2021 | 18.8K | 128.9K | — |
| Brigham Michael FDirector · 14 transactions | — | 229.8K | 87.5K | 53.5K | — |
| Crabb Joseph HFormer VP and CSO · 40 transactions | — | 142.8Kas of Mar 2022 | 60.5K | 26.5K | 10.0K |
| Tomsche David ScottDirector · 113 transactions | — | 131.4K | — | 88.8K | — |
| Pessin Brian L.See Explanation of Responses · 1 transaction | — | 70.0Kas of Jul 2017 | — | 30.0K | — |
| Cashen Anthony BDirector · 3 transactions | — | 45.3Kas of Apr 2006 | — | — | 15.0K |
| te Boekhorst Paul Francis OlivierPresident and CEO, Director · 3 transactions | — | 17.8K | — | 14.0K | — |
| Cunningham DavidDirector · 22 transactions | — | 16.0Kas of Jun 2022 | 15.0K | 13.4K | — |
| Brockmann Bobbi JoDirector · 5 transactions | — | 8.5Kas of Dec 2020 | 7.5K | — | — |
| Rhodes LindaDirector · 12 transactions | — | 7.2Kas of Aug 2017 | 2.0K | 5.2K | — |
| Wainman Paul RDirector · 8 transactions | — | 6.3Kas of Mar 2019 | 4.3K | 2.0K | — |
| Basse Gloria FDirector · 1 transaction | — | 3.5Kas of Jun 2025 | 3.5K | — | — |
| Bruce Robert CDirector · 1 transaction | — | 1.0Kas of Nov 2007 | — | 1.0K | — |
| Gathagan Bryan K.Director · 1 transaction | — | 1.0Kas of Jun 2025 | — | 1.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +509.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.